Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2674MR)

This product GTTS-WQ2674MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2674MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2819MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ3185MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ2245MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ7937MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ7152MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ15557MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ3456MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ4252MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW